

November 2, 2015



## **Imeglimin's Innovative Mitochondria-Targeted Mechanism of Action Recognized by the Scientific Committee of the World Mitochondria Society**

### **Best Short Oral Communication Award for Poxel at the 6<sup>th</sup> World Congress on Targeting Mitochondria in Berlin**

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL) a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that the Company's presentation, 'Imeglimin, a New Mitochondria Targeted Agent for Type 2 Diabetes Treatment', was selected as the Best Short Oral Communication at the 6<sup>th</sup> World Congress on Targeting Mitochondria in Berlin, Germany, 30 October, 2015. The presentation was awarded for providing insights into the unique mitochondrial mechanism of action for Imeglimin, Poxel's first-in-class oral anti-diabetic agent leading to its ability to increase both glucose-dependent insulin secretion and sensitivity, the two key defects of type 2 diabetes. The congress is organized by the World Mitochondria Society (WMS) and headed by the Society's President, Professor Volkmar Weissig. It covers a variety of new strategies and innovations as well as clinical applications in mitochondrial medicine.

*"We are truly honored and thankful to the WMS Scientific Committee for this award that recognizes the quality of our work and the innovative mechanism of action of our drug candidate, Imeglimin, a new antidiabetic agent, targeting the mitochondria for the management of type 2 diabetes,"* stated Sebastien Bolze, Ph.D., EVP Non-Clinical Development and CSO of Poxel.

*"Each year, the WMS recognizes a company which has made significant contributions to translating their research into real applications for the management and prevention of disease progression,"* stated Marvin Edeas, M.D., Ph.D., Professor and Chairman of the World Mitochondria Society. *"As chairman of the scientific committee, I was highly intrigued by the study presented by Dr. Bolze. He clearly outlined how this new drug can modulate mitochondria function and how these effects can affect insulin sensitivity and secretion. Additionally, the effects on oxidative stress reduction and cell protection were also highlighted."*

### **About the World Mitochondria Society**

The World Mitochondria Society (WMS) was founded in 2010 by Professor Marvin Edeas. The idea of WMS is to bring a new level of understanding of mitochondria science out of the classical existing point of view. The WMS organizes Targeting Mitochondria World Congress each year in Berlin. WMS is a non-profit international organization. In no case, part of its assets or incomes shall benefit to any private or individual partnership or corporation.

## **About Poxel**

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japanese subjects. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxel.com](http://www.poxel.com))

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151102006275/en/>

## **Investor relations / Media - EU/US**

MacDougall Biomedical Communications

Gretchen Schweitzer or Anca Alexandru, + 49 89 2424 3494

[aalexandru@macbiocom.com](mailto:aalexandru@macbiocom.com)

or

## **Investor relations / Media - France**

NewCap

Florent Alba/Nicolas Mérieau, + 33 1 44 71 98 55

[poxel@newcap.fr](mailto:poxel@newcap.fr)

Source: Poxel